Anti-HBs response in seroconverting chronic HBV carriers following alpha-interferon treatment.
The antibody response to hepatitis B surface antigen (anti-HBs) was studied in 15 chronic hepatitis B virus (HBV)-infected patients who seroconverted following treatment with alpha interferon. The levels of anti-HBs (IU/l) attained were significantly lower than those recorded in patients with convalescent symptomatic or asymptomatic acute infection and in hospital personnel who received a plasma derived HBV vaccine.
Karayiannis
P
P
Department of Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London, United Kingdom.
Kanatakis
S
S
Thomas
H C
HC
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000276:immunology*; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007370:Interferon Type I / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D000906:Antibodies; D006514:Hepatitis B Surface Antigens; D007370:Interferon Type I